UNSPSC 51386603: Aloe/hydrocortisone/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386603 Aloe/hydrocortisone/pramoxine is a Commodity code that in recent state and local activity covers pharmaceutical and over-the-counter product procurement, though the code's nominal scope and actual solicitation activity show significant misalignment. State and local governments have posted opportunities for naloxone and drug deactivation systems, generic multi-source pharmaceuticals supplied through authorized wholesalers, and direct-to-manufacturer prescription programs, none of which align with the topical therapeutic ingredients the code name suggests. The issuing bodies span health authorities, state procurement offices, and cooperative purchasing alliances: Seminole County, Florida (county health authority), the Texas Health and Human Services Commission (state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative vehicle serving state and local government facilities). The mix reflects both direct county procurement and cooperative purchasing models that serve multiple jurisdictions.

Recent opportunities show activity concentrated in Florida and Texas, with multi-state participation through Minnesota's cooperative purchasing vehicle. Seminole County issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with bids due July 26, 2023 (note: the due date appears to predate the posting date, suggesting a data error in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no formal award timeline specified at the information-gathering stage. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract performance beginning July 1, 2026. The code shows limited recent activity and poor alignment between its nominal scope and actual procurement content.